Clinical Trial Update: COLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal Cancer [EARLY_Phase 1]

View source ↗

Summary

Clinical trial update announcing COLONYVAQ, a personalized neoantigen vaccine for colorectal cancer, currently in an early-phase 1 trial and recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• COLONYVAQ

Snippet

Sponsor: Biogenea Pharmaceuticals Ltd. | Conditions: Colorectal Cancer Metastatic, Colorectal Cancer Stage III | EARLY_Phase 1 | Status: RECRUITING